Member Info for NoviceChaser

It was no tv this week that there is a shortage of NHS staff providing cancer treatment and that it’s effecting treatments and runs the risk of. Ineffective treatments. If there is a short delay then we will just have to wait. As discussed earlier does anyone know the shell life of first batch.

Great oversight by everyone, as always. If any of you have a spare 5 minutes I would welcome you having a look at CRTX and post a comment on that board as I am equally invested in both companies and would appreciate your views, fully understand if not interested.

I am invested for the medium term. As the company themselves have stated we are moving to a platform with the pre clinical development of the prostrate cancer treatment. Previously the company have stated they are looking to sell or go into a partnership before the commercial end point, my own personal view is as follows:

1. No guarantees phase 2 trails will be successfully.

2. If the safety and efficiency are proven for the phase 2 trial, them we should see a major rerate.

3. If they build the platform to include breast and other cancers then this should make the company more attractive for a buy out, at a greater price.

4. Not sure how much we would be valued at as we are not a new drug, but a delivery system.

5. No idea if tier 1 pharmas will be looking at the delivery system as a means of testing previous trail drugs they have developed but could not get past the blood / brain barrier or would consider using chemo drugs plus their drugs (as the seed can carry more than 1 drug).

Plenty of risks and opportunities. Anybody fancy an estimate at what the company would be worth if phase 2 stage 1 trial is successful and we have preclinical data for 3 or 4 other types of cancer treatment?

The grant from Innovate UK under the Biomedical Catalyst is from 2025. Does this mean that the grant was awarded a while ago but has only just been announced as phase 2 is about to start any day?

As previously stated by the company: CRISM Therapeutics is fully funded to initiate the initial 12-patient, dose-escalation portion of its Phase 2 clinical trial for its ChemoSeed cancer treatment. The funding and setup costs are being covered by proceeds from a £1,000,000 share placing and a separate £100,000 retail offer. There has obviously been some slippage as the first patient was due to be treated in Q1 hence one of the reasons for today’s announcements.

I an invested in this share and have a reasonable amount invested in another 2 companies as well. Thankfully this board and one of the other boards are very good ( every body has different views but share information) the other board is nasty, I just hope that when the pump and dump crews arrive that long term holders can provide clarity. I am no expert but I am sure that this is a good long term investment.

Watched at news article on local tv a few weeks ago where they talked this form of cancer and not having any gains on life expectancy for many years (about 10 to 15 years and no progress, if I remember correctly). Even a small gain using chemoseed would be a major step forward.

I know it is an open trial, but could the next RNS be when the first patient has been treated and initial data lands, 5 to 6 weeks later?

Next RNS on Wednesday

https://www.google.com/search?q=genflow+next+rns+13th+of+may&client=safari&hs=pZCV&sca_esv=6240a4551174a4e8&hl=en-gb&udm=50&fbs=ADc_l-ZexlP7EBCNvIngZQ0PrpGnde5EenWPl3ujHKe4IVU9DPvUHpXUr4FRBILrvrNAVeIPgPlesd3nC1tHt5WuMWdwrZU2z6_GHLE8tb4bVHz5S51tLLaoxLIURjtOAZfCR5JL7s9Z19PqMEYh8q7-liXUF6p2o3xE4N44XmuZxWyh6KI1bKGeZ6eX-pXj-lvY4hmhsUFSHQX-98eUbtDG_8DqqWbEm1TbSoul-sABw_1Dc2VFwBI&aep=1&ntc=1&sa=X&ved=2ahUKEwi_0KDj1LCUAxUoV0EAHd1tFNwQ2J8OegQIDBAE&biw=375&bih=488&dpr=2&mstk=AUtExfBOyER3kUSVXab9u8Outd8Ka7Cvpn3Nz8ETofX6V5n3m9eRrD3nvi7ds5ZZA-EEq0ha9mwRGYD_V10OjC-nBjGGeC8tlhtZQPHuY7sWzPNtRU2Al376e35dcUvXA6a21VVIuKk6cjx9lnvYVWpuaT1k7EfvUuLcVPk&csuir=1